7-117530974-C-G
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000492.4(CFTR):āc.349C>Gā(p.Arg117Gly) variant causes a missense change. The variant allele was found at a frequency of 0.0000527 in 1,613,576 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R117C) has been classified as Pathogenic.
Frequency
Consequence
NM_000492.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.349C>G | p.Arg117Gly | missense_variant | 4/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.349C>G | p.Arg117Gly | missense_variant | 4/27 | 1 | NM_000492.4 | ENSP00000003084.6 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152174Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 250944Hom.: 0 AF XY: 0.0000295 AC XY: 4AN XY: 135604
GnomAD4 exome AF: 0.0000547 AC: 80AN: 1461402Hom.: 0 Cov.: 31 AF XY: 0.0000426 AC XY: 31AN XY: 726990
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152174Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74330
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:5Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 117 of the CFTR protein (p.Arg117Gly). This variant is present in population databases (rs77834169, gnomAD 0.004%). This missense change has been observed in individuals with clinical symptoms of CFTR-related conditions (PMID: 11119745, 29805046, 29944384, 30888834). ClinVar contains an entry for this variant (Variation ID: 53762). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CFTR protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects CFTR function (PMID: 29805046). This variant disrupts the p.Arg117 amino acid residue in CFTR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 7525450, 7529962, 11788090, 15482777, 21520337, 21783433, 22658665, 23974870, 24586523). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 04, 2022 | The p.R117G pathogenic mutation (also known as c.349C>G), located in coding exon 4 of the CFTR gene, results from a C to G substitution at nucleotide position 349. The arginine at codon 117 is replaced by glycine, an amino acid with dissimilar properties. The mutation has been reported as a variant of varying clinical consequences (VVCC) (Sosnay PR et al. Pediatr. Clin. North Am., 2016 08;63:585-98; The Clinical and Functional TRanslation of CFTR (CFTR2); available at http://cftr2.org. Accessed November 14, 2018). It has been described in the heterozygous state in a male with congenital bilateral absence of the vas deferens (CBAVD); a second CFTR alteration was not observed (Claustres M et al. Hum. Mutat., 2000;16:143-56; Daudin M et al. Fertil. Steril., 2000 Dec;74:1164-74). In addition, this mutation was observed in conjunction with p.N34S in the SPINK1 gene in an individual with idiopathic pancreatitis (Masson E et al. PLoS ONE. 2013; 8(8):e73522). In an in vitro study, the R117G protein had 35% of normal CFTR function (Raraigh KS et al. Am. J. Hum. Genet., 2018 Jun;102:1062-1077). Based on internal structural analysis, this variant is more disruptive than known pathogenic variants at the same position and in the same region (Liu F et al. Cell, 2017 03;169:85-95.e8). Furthermore, there are also multiple pathogenic alterations at this same position, including p.R117H and p.R117C (Thauvin-Robinet C et al. J. Med. Genet., 2013 Apr;50:220-7; Sosnay PR et al. Nat. Genet., 2013 Oct;45:1160-7). Based on available evidence to date, this variant has not been reported as causative of classic CF; however, it may contribute to the development of a CFTR-related disorder and is thus classified as as a disease-causing mutation. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Aug 17, 2019 | Previously reported disease-causing CFTR variant associated with varying clinical consequences. See www.CFTR2.org for phenotype information. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 22, 2021 | - - |
Uncertain significance, flagged submission | clinical testing | Counsyl | Nov 08, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 21, 2023 | Variant summary: CFTR c.349C>G (p.Arg117Gly) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 250944 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.349C>G has been reported in the literature in multiple compound heterozygous individuals affected with Cystic Fibrosis (Desai_2018, McCague_2019) as well as in individuals with pancreatitis (e.g., Masson_2013) and congenital bilateral absence of the vas deferens (e.g., Daudin_2000). These data indicate that the variant is very likely to be associated with disease. Experimental evidence evaluating an impact on protein function demonstrated the variant results in approximately 35% overall function (compared to WT) (Raraigh_2018). Eight ClinVar submitters (evaluation after 2014) have cited the variant, with six submitters classifying the variant as pathogenic (n=3)/likely pathogenic (n=3), and two submitters classifying the variant as uncertain significance. Additionally, different missense variants affecting the same codon have been reported as pathogenic by our lab (p.R117C, p.R117H, p.R117L).Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Aug 10, 2019 | The CFTR c.349C>G; p.Arg117Gly variant (rs77834169) has been described in individuals with cystic fibrosis (CF) when found in trans to another CF-causing variant, but has also been described in association with other CFTR-related disorders such as congenital bilateral absence of vas deferens or pancreatitis in individuals that do not have CF (see link to CFTR2 database, Daudin 2000, Masson 2013). This variant is reported in ClinVar (Variation ID: 53762) and is found in the general population with an overall allele frequency of 0.002% (6/282344 alleles) in the Genome Aggregation Database. The arginine at residue 117 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.773). Due to this variant having a variable presentation in affected individuals, it is considered to be pathogenic with varying clinical consequences. References: CFTR2 database: http://www.cftr2.org/ Daudin M et al. Congenital bilateral absence of the vas deferens: clinical characteristics, biological parameters, cystic fibrosis transmembrane conductance regulator gene mutations, and implications for genetic counseling. 2000;Fertil Steril. 74(6):1164-74. Masson E et al. A conservative assessment of the major genetic causes of idiopathic chronic pancreatitis: data from a comprehensive analysis of PRSS1, SPINK1, CTRC and CFTR genes in 253 young French patients. 2013;PLoS One. 8(8):e73522. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jun 26, 2024 | The CFTR c.349C>G (p.Arg117Gly) variant has been reported as a variant of varying clinical consequences (VVCC) (PMID: 36409994 (2022) and CFTR2 (https://cftr2.org/)). This variant has been observed in individuals with clinical symptoms of CFTR-related conditions (PMIDs: 29944384 (2018)) and 30888834 (2019)) including individuals with pancreatitis (PMIDs: 18687795 (2008) and 23951356 (2013)) and congenital bilateral absence of the vas deferens (PMIDs: 11119745 (2000) and 10923036 (2000)). Experimental studies have indicated that the variant has reduced CFTR activity compared to the wild type CFTR, however the effect is still inconclusive (PMIDs: 29805046 (2018), 30888834 (2019), and 38388235 (2024)). In addition, other pathogenic variants have been reported at the same positions, including p.R117H and p.R117C (PMIDs: 19880712 (2009) and 23974870 (2013)). The frequency of this variant in the general population, 0.000039 (5/128904 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. ClinVar contains an entry for this variant (URL: www.ncbi.nlm.nih.gov/clinvar, Variation ID: 53762). Based on the available information, this variant is classified as likely pathogenic. - |
CFTR-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | curation | CFTR-France | Jan 18, 2021 | - - |
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 15, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at